Key clinical point: Use of handheld devices to collect cardiac implant data led to a high rate of scheduled data transmissions.
Major finding: Patients who relayed data with a personal device and app succeeded in sending 95% of their scheduled transmissions.
Study details: A multicenter, single-arm study with 245 patients followed for 12 months and compared with various historical controls.
Disclosures: The BlueSync Field Evaluation study was sponsored by Medtronic, the company that markets Bluetooth-enabled cardiac devices. Dr. Tarakji has been a consultant to Medtronic, and also to AliveCor, Boston Scientific, and Johnson & Johnson.
Tarakji KG et al. Heart Rhythm Society 2020, Abstract D-LBCT04-05.